SHAARE ZEDEK MEDICAL CENTER

Merck KGaA Joins Peregrine Ventures' Incentive Incubator as Strategic Partner

8 days ago

• Merck KGaA has become a strategic partner in Peregrine Ventures' Incentive Incubator, gaining early access to startups in bioconvergence, pharma, and biotechnology fields. • The collaboration will focus on ventures with significant market potential aligned with Merck's three global divisions: Healthcare, Life Science, and Electronics, with priority given to bioconvergence ventures. • Through this partnership, eligible startups will receive support including investments, regulatory guidance, business development assistance, and potentially early-phase trial planning.

Relmada Therapeutics Secures Licensing for Novel Bladder Cancer Treatment NDV-01

2 months ago

• Relmada Therapeutics has acquired exclusive worldwide rights to NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, with Phase 2 data expected in April 2025. • NDV-01 offers significant advantages over conventional treatments, including 10-day sustained drug release versus hours for traditional delivery, potential for outpatient administration, and a strong safety profile based on established chemotherapy agents. • The licensing agreement includes a $3.5 million upfront payment plus 10% equity stake to Trigone Pharma, with potential milestone payments up to $200 million, targeting a U.S. market with approximately 600,000 NMIBC patients.

ctDNA Testing Shows Promise in Guiding Breast Cancer Treatment Decisions

5 months ago

• A study reveals ctDNA analysis offers a deeper understanding of the genetic makeup of advanced breast cancer, enabling more personalized treatment approaches. • ctDNA testing influenced treatment decisions in 35% of advanced breast cancer cases, potentially improving outcomes and reducing resistance. • Baseline ctDNA levels correlate with tumor size and endocrine therapy sensitivity in HR-positive early breast cancer, according to the PELOPS trial. • Ultra-sensitive ctDNA testing may predict long-term outcomes and guide systemic treatment decisions in early breast cancer, warranting further investigation.